



Hemorrhagic Fever Virus Therapeutics Medical Countermeasures (HFV-Tx MCM) Acquisition Program

Description

JPM-TMT's HFV-Tx MCM acquisition program provides platform-based capabilities to ameliorate the effects of HFV exposure for which there are no vaccines or treatments available. The design concept is to develop a US Food and Drug Administration (FDA)-licensed MCM targeting viruses in the Filoviridae family, which include Ebola and Marburg viruses. The selected platform will initially produce US FDA-approved MCMs against Ebola and Marburg viruses. The program is designed to mitigate the effects of these viruses and genetically similar viruses. These efforts also will further the advancement of platform technologies that may be used to generate MCM for other viral pathogens.



Mission

Provide therapeutics to ameliorate the effects of exposure to viruses that cause hemorrhagic fevers

Capabilities

Users

Reserves, National Guard Bureau, Civil Support Teams, USSOCOM, US Navy, US Marine Corps, US Coast Guard, US Army, US Air Force

Status

Technology Development - Anticipated Fielding: FY 2017 Q4

This Fact Sheet was cleared for public release on 2/6/2013.

Point of Contact: Chemical, Biological, Radiological, & Nuclear Information Resource Center (CBRN IRC), CBRN.IRC@us.army.mil,
Toll Free: 1-800-831-4408, Commercial: (309) 782-7349, DSN: 793-7349, Fax: (309) 782-1919
